Improving the Therapeutic Efficacy and Bioavailability of Carvedilol for Control of Diabetes-Associated Heart Failure: In Vitro and In Vivo Characterization
{{output}}
Carvedilol (CRD) is an oral beta-adrenergic antagonist approved for treating heart failure (HF). However, due to its short half-life and poor solubility, CRD has limited bioavailability and effectiveness. This study aimed to develop a nasal spray of CRD-novaso... ...
